Eli Lilly and Company

Songqing Na

Barrett Allan

Catherine Brautigam Beidler

Rohn Lee Millican, Jr

Neungseon Seo

Shane Krummen Atwell

Jeffrey Streetman Boyles

Yiqing Feng

David John Stokell

Kira Vladimirovna Rubtsova

Diana Isabel Ruiz

Alison Lee Sim Budelsky

Guifeng Zhang

Maya Rachel Karta

Donmienne Leung

Laura Anne Pelletier

Catherine B Beidler

Rohn L Millican

The present disclosure relates to antibodies that specifically bind human IL-4Rα, compositions comprising such IL-4Rα antibodies, and methods of using such IL-4Rα antibodies.

Human interleukin-4 receptor alpha antibodies

The present disclosure relates to antibodies that bind human CD19 ('anti-human CD19 antibodies' or 'anti-human CD19 antibodies'), compositions comprising such anti-human CD19 antibodies, and methods of using such anti-human CD19 antibodies.

Anti-human CD19 antibodies

Bispecific antibodies are provided that bind Tumor Necrosis Factor alpha (TNF&#x3b1;) and the p19 subunit of Interleukin-23 (IL-23p19) and are characterized as having high affinity and strong simultaneous neutralizing properties to both TNF&#x3b1; and IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease and Ulcerative Colitis, Axial Spondyloarthropathy, Rheumatoid Arthritis and Psoriatic Arthritis.

Anti-TNF-/anti-IL-23 bispecific antibodies

Growing community of inventors

San Marcos, CA, United States of America

Songqing Na